myasthenia gravisneonatal Fc receptor antibodyrituximabthymectomyDespite the availability of an increasing variety of disease‐modifying therapies, the proportion of patients with generalized myasthenia gravis ( MG ) who achieved the practical treatment goal remained low at approximately 50%‐60% in our ...
For AChR-MG, the most common form of the disease, Overview of traditional immunotherapies in Myasthenia gravis The management of MG has long relied on several cornerstone immunotherapies aimed at mitigating the autoimmune attack on the neuromuscular junction. These treatments include AChE-I, corticostero...
This article presents a summary of the new medications approved for generalized myasthenia gravis (gMG) since 2017. Pivotal clinical trials that led to the
because this is best done by experts in a therapeutic area. Similarly, we do not discuss drug pricing for novel treatments. Such discussion can only be meaningful based on input from experts within a specific therapeutic area who can judge on the added...
Efgartigimod is an antibody fragment designed to reduce pathogenic IgG antibodies and block the IgG recycling process in patients with generalized myasthenia gravis.
Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition. ...
Lupus nephritis (LN) is the most common severe complication of SLE, and studies have shown that 60% of SLE patients will develop LN during the course of their disease[1], making it a major cause of high mortality in SLE patients. Current standard-of-care treatments for SLE have limited ...
The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minut
CIDP. Both procedures are invasive and must be done in a clinical setting. Corticosteroids may also be used to treat the condition, but chronic use of such anti-inflammatory agents comes with a wide range of complication risks. These currently available treatments do not work for all CIDP ...
However, the use of quinidine (contra indicated in all other myasthenic disorders) and fluoxetine, which reduce the duration of acetylcholine receptor channel openings, are both predictably effective treatments for the slow channel syndrome. The "congenital myasthenic syndrome associated with ...